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Abstract: The role of the nucleic acids in prion aggregation/disaggregation is becoming more and
more evident. Here, using HET-s prion from fungi Podospora anserina (P. anserina) as a model system,
we studied the role of RNA, particularly of different domains of the ribosomal RNA (rRNA), in
its aggregation process. Our results using Rayleigh light scattering, Thioflavin T (ThT) binding,
transmission electron microscopy (TEM) and cross-seeding assay show that rRNA, in particular
the domain V of the major rRNA from the large subunit of the ribosome, substantially prevents
insoluble amyloid and amorphous aggregation of the HET-s prion in a concentration-dependent
manner. Instead, it facilitates the formation of the soluble oligomeric “seeds”, which are capable
of promoting de novo HET-s aggregation. The sites of interactions of the HET-s prion protein on
domain V rRNA were identified by primer extension analysis followed by UV-crosslinking, which
overlap with the sites previously identified for the protein-folding activity of the ribosome (PFAR).
This study clarifies a missing link between the rRNA-based PFAR and the mode of propagation of the
fungal prions.
Keywords: ribosomal RNA; prion aggregation; P. anserina prion protein HET-s; PFAR
1. Introduction
Prions are infectious proteins that can self-propagate and transmit their fibrillary amyloid
conformation to normal indigenous prion proteins [1]. Prions can cause fatal neurodegenerative
diseases that affect both humans and other animals. These diseases, called in general Transmissible
Spongiform Encephalopathy (TSE), include Bovine Spongiform Encephalopathy (BSE or mad cow
disease), Scrapie in sheep, Creutzfeldt–Jakob disease and Kuru in humans [1,2], etc. These diseases are
caused by aggregation of the prion protein PrP in the amyloid form, which is a product of the PRNP
gene in humans [3–6]. Besides mammalian prions, several prion-forming proteins were identified
in fungi as well. While the biological significance of prion-forming proteins in fungi is somewhat
unclear [7], most yeast prions are functional prions having a fibrillar structure similar to the mammalian
prions [8], although, so far, there is no evidence for cross-nucleation of the mammalian prions with
fungal prions. Thus, fungal prions have provided suitable and safe models for understanding the
folding, aggregation and propagation mechanisms of disease-forming mammalian prions.
HET-s is a prion protein that corresponds to the [Het-s] prion system in the filamentous fungi
Podospora anserina (P. anserina) [9]. It was initially identified as a part of a non-self-recognition
process [10,11] that controls vegetative incompatibility in this fungus [12]. There are two antagonistic
allelic variants of this protein: HET-s and HET-S, which are of the same length (289 amino acids) but
differ in the sequence for 13 amino acids. The HET-s is a two-domain protein with a C-terminal domain
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(residues from 218 to 289) that is known as the prion-forming domain (PFD), and an α-helical globular
N terminal domain (amino acid 1 to 227), also called the HeLo domain. The HeLo domain partially
overlaps with the PFD [13–15]. The PFD of HET-s is composed of a two-fold repetition of 21 amino
acids in an elementary triangular motif and adopts a β-solenoid structure with two layers of β-strands
per monomer. Each of the repeated motifs composes one layer of the β-solenoid structure [16–18].
When a strain of the fungus carrying the HET-s prion encounters a strain that expresses a
non-prion-forming form of the protein HET-S, the heterokaryon formed on cell fusion dies due to
protein incompatibility [11]. Although the mechanism of cell death remains unclear, it is proposed that
the incompatibility arises from the conversion of HET-S protein to β-solenoid rich prion conformation
under influence of HET-s—the prion-forming form of the protein [14]. The structure of the PFD of
HET-s has been solved by solid-state NMR [19]. Moreover, the correlation between structure and
infectivity of HET-s has also been investigated by cryo-EM [20]. Thus, HET-s constitutes a good model
system for studying prion aggregation and disaggregation.
It has been reported that ribosomes from bacterial, archaeal and eukaryotic sources can refold a
large number of denatured proteins to their active state [21]. For all proteins tried so far, ribosome
assisted folding showed a remarkably higher gain of activity compared to that achieved by spontaneous
folding. The protein-folding activity of the ribosome (in short “PFAR”) [22–26] has been assigned
to the large subunit of the ribosome, and more specifically, to the domain V of the main ribosomal
RNA (rRNA; 23S in bacteria/25S in yeast/28S in higher eukaryotes) from the large subunit of the
ribosome. Earlier reports have described PFAR as a specific target for two antiprion compounds
6-aminophenanthridine (6AP) and guanabenz acetate (GA) [27–29]. It has been shown that these
compounds bind to the domain V of 23S/25S rRNA on specific nucleotides and competitively occludes
interaction of the protein-folding substrates with domain V rRNA [28]. Since 6AP and GA reverse
[PSI+] prion phenotype in vivo, it was proposed that PFAR is involved in prion processes [24,27,30].
Recently there are more reports for the involvement of PFAR in prion propagation in yeast [31,32].
The involvement of the nucleic acids in protein aggregation and disaggregation has been
demonstrated with both DNA and RNA [33]. It has been shown using recombinant mammalian prion
protein (rPrP) as a model system that nucleic acid interactions lead to different aggregated species
of rPrP depending on the sequence and the size of the oligonucleotides [34]. Another earlier report
claimed that prion formation in the budding yeast Saccharomyces cerevisiae (S. cerevisiae) was induced
by the expression of rRNA from a plasmid-based rDNA construct [35]. Recent studies from our group
showed that RNA can modulate aggregation of the core domain of the tumor suppressor protein
p53 [36] and the rPrP [37]. Related results from other groups also showed that the Escherichia coli (E.
coli) ribosome can prevent aggregation of partially folded protein intermediates [38]. However, so
far, the role of rRNA in prion protein aggregation has remained elusive. In the present work, we
have studied the role of various RNAs, including rRNA, mRNA and tRNA, in the aggregation of
HET-s using Rayleigh light scattering and Thioflavin T (ThT) binding assays. We find that rRNA,
especially the domain V of 23S/25S/28S rRNA, from various sources prevent the formation of large
fibrillar aggregates of HET-s; this is also visualized with transmission electron microscopy (TEM). In
contrast, “oligomeric seeds“ of HET-s are formed, which facilitate aggregation of fresh HET-s samples,
as demonstrated with cross-seeding assays. Furthermore, using UV-crosslinking followed by primer
extension assay we have identified HET-s interaction sites on the domain V of 23S rRNA and studied
the effect of mutagenesis on the specific nucleotides. Our study demonstrates that rRNA-based PFAR
can play an important role in modulating aggregation and propagation of the prions.
2. Results
2.1. rRNA Inhibits Aggregation of HET-s Prion as Monitored by Rayleigh Light Scattering
HET-s protein purified in urea denatured state was subjected to aggregation by incubation in
50 mM pH 7.5 Tris-HCl buffer overnight (8–12 h) at 37 ◦C and the extent of aggregation was followed by
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measuring Rayleigh light scattering at 402 nm. While freshly diluted HET-s showed only background
level, a significant increase in light scattering was seen after overnight incubation of HET-s, indicating
large aggregate formation in the HET-s sample. In order to study whether RNA and in particular
rRNA influences HET-s aggregation, overnight incubation of HET-s was conducted in the presence
of different RNA samples at a fixed concentration. These included bulk tRNAs isolated from E. coli
MRE600, in vitro transcribed mRNAs from two unrelated proteins—(i) E. coli dihydrofolate reductase
(DHFR) and (ii) human carbonic anhydrase I (HCA), and different domains of E. coli 23S rRNAs. Since
full-length 23S rRNA produces high background scattering, individual domains of E. coli 23S rRNA
were transcribed and subjected to this assay.
As shown in Figure 1A,B, addition of mRNAs or tRNAs did not show any significant change in
light scattering suggesting that they do not influence HET-s aggregation. In contrast, a moderate to
significant decrease in light scattering was seen with different domains of rRNAs. Domain V of 23S
rRNA showed the highest reduction in light scattering, which suggests that this highly conserved
rRNA domain strongly inhibits HET-s aggregation. Domains IV and II of 23S rRNA were also quite
effective in reducing HET-s aggregation. It is worth mentioning that the domain V of 23S rRNA hosts
peptidyl transferase center as well as the active sites for PFAR and the domains IV and II are closely
associated with it.
Next, in vitro transcribed domain V rRNAs from large ribosomal subunit from various prokaryotic
(E. coli, Bacillus subtilis (B. subtilis)) and eukaryotic (yeast S. cerevisiae, human, human mitochondria)
sources were tested in HET-s aggregation assay. As shown in Figure 1C,D, all domain V rRNAs
showed a comparable level of reduction in light scattering. This result suggests that in addition to
peptidyl transfer and PFAR, prevention of protein aggregation is likely another conserved function
of the domain V of 23S/25S/28S rRNA, irrespective of prokaryotic or eukaryotic origin. Further,
upon titration of domain V rRNA (E. coli) gradual reduction of light scattering was observed in
a concentration-dependent manner (Figure 1E,F). However, unlike PFAR, where a 1:1 molar ratio
of the sample protein and domain V of rRNA is required for the highest extent of protein-folding,
substoichiometric or relatively lesser concentration of domain V rRNA than the protein HET-s was
sufficient for largest reduction of its aggregation. Our results indicate that rRNA especially the domain
V of 23S rRNA can prevent the formation of large aggregates of the HET-s prion.
2.2. ThT Binding Demonstrates That rRNA Prevents Fibrillar Aggregation of HET-s
ThT binding assay is frequently used for the quantitative determination of amyloid fibril formation
as its fluorescence increases specifically by binding to mature β-sheet enriched amyloid fibrils [39,40].
We have probed HET-s aggregation with ThT fluorescence under conditions identical to light scattering
measurements. ThT was added just before fluorescence measurement, which excluded any effect of
ThT on HET-s aggregation process.
As shown in Figure 2, ThT fluorescence increased significantly upon HET-s aggregation. This
observation suggests that most likely HET-s aggregates to fibrillar amyloids, which is in good agreement
with earlier reports [41]. Further, we analyzed the effect of the 23S rRNA domains (Domains II, IV, V of
23S rRNA from E. coli) in the ThT binding assay since these RNAs caused a significant reduction in
light scattering by HET-s aggregates (Figure 2, inset). The bulk tRNAs isolated from E. coli, which did
not have a pronounced effect in the light scattering assay was used as a control. Larger RNAs could
not be used in this assay due to high background fluorescence of ThT with just RNAs. As expected, the
bulk tRNAs did not reduce ThT fluorescence. However, all 23S rRNA domains lead to a decrease in
ThT fluorescence (Figure 2, inset). Again, the highest reduction was seen with domain V of 23S rRNA.
Moreover, the degree of reduction in ThT fluorescence with different 23S rRNA domains (Figure 2,
inset) followed the same trend as seen in the light scattering assay (Figure 1E,F). This result confirms
that rRNAs, especially the domain V of 23S rRNA, prevent amyloid aggregation of the HET-s prion.
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Figure 1. The effect of RNAs in HET-s aggregation as followed by Rayleigh light scattering at 402 nm.
HET-s protein stored in a denatured condition in 8 M urea was diluted in 50 mM Tris-HCl pH 7.5 to a
final concentration of 5 µM and incubated without or with different RNA samples (~1 µM) overnight
at 37 ◦C for aggregation. Then, light scattering was measured with a HITACHI F-7000 fluorescence
spectrophotometer. While the left panels show emission peak intensities at 402 nm (excitation 400 nm;
average of three to five independent experiments, error bars represent standard deviation), the right
panels show representative spectra using the same color codes as in the corresponding left panels.
Light scattering from HET-s (A,B) without or with different RNA samples, (C,D) with domain V of
rRNA from various sources and (E,F) with different concentrations of domain V rRNA from E. coli.
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Figure 2. The effect of different RNAs on HET-s aggregation monitored by ThT binding. HET-s
aggregation was induced as mentioned in the Materials and Methods section and tested for ThT binding.
The curve shows resulting ThT fluorescence (Emission 483 nm, excitation at 450 nm) with time. The
inset represents the saturating values of ThT fluorescence (at 483 nM) without (gray bar) or with various
RNAs as indicated. The data presented here are average of three independent measurements and the
error bars represent standard deviation.
2.3. HET-s Aggregates Show Different Morphology with or without RNAs as Seen by TEM
We have analyzed the aggregation morphology of HET-s proteins by TEM. As expected, after
overnight aggregation reaction, the free HET-s protein forms typical amyloid fibrils (Figure 3A).
Interestingly, when the aggregation reaction was done in the presence of domain V of 23S rRNA we
have noticed, not only, a change in the fibril morphology, but also, a vast decrease in the amount of
HET-s aggregation (Figure 3B). Our results showed that HET-s alone forms long amyloid fibrils as well
as clustered aggregates from which the long fibrils emerge. In contrast, in the presence of domain V
of 23S rRNA (E. coli), the fibrillar structures disappeared; instead, scattered smaller aggregates with
spherical and branched structures were observed. Interestingly, RNAs could be seen as black dots
among the HET-s aggregates as they bind better to uranyl ions supplied in the reaction as acetate
salt. When other RNAs (e.g., DHFR mRNA, HCA mRNA) were tested with HET-s, various aggregate
morphologies could be seen, which were different from the HET-s alone, but not free from fibrillar
structures (Figure 3C,D). They caused accumulation of several intermediate aggregate structures, but
the reduction of aggregation was not to the same extent as with domain V of 23S rRNA. This result
visibly confirms that domain V rRNA effectively reduces and alters HET-s aggregation morphology.
2.4. Cross-Seeding Assay Demonstrates That Domain V of 23S rRNA Aids in Formation of The HET-s
“Oligomeric Seeds“
To determine how domain V rRNA affects the HET-s fibril formation, aggregation kinetics of
HET-s was followed by Rayleigh light scattering (Em. 402 nm, Ex. 400 nm) for HET-s alone or with
domain V of 23S rRNA (E. coli; Figure 4). HET-s alone started aggregation immediately after dilution
of the denaturant and light scattering increased with time suggesting gradual aggregation of the
protein. When domain V rRNA was added with HET-s, both the rate and the amplitude of light
scattering decreased dramatically (Figure 4), suggesting that significantly smaller amounts of large
HET-s aggregates populated in the presence of the domain V rRNA. This result is in full agreement
with end-point measurements presented in Figure 1A,B. However, to test whether the domain V rRNA
aids in the formation of the oligomeric amyloid “seeds“, as also seen for murine rPrP [37], we designed
a cross-seeding assay. For that, we first set HET-s aggregation reactions without and with domain V of
23S rRNA by incubating overnight at 37 ◦C. Then, the supernatant was collected after centrifuging
down the large HET-s aggregates. A small volume of the cleared supernatant (10 µL) was added into a
fresh HET-s aggregation reaction (500 µL) and then HET-s aggregation was followed with time using
Rayleigh light scattering as described above. In both cases, we observed a pronounced and faster
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increase in light scattering as would be expected from seeded aggregation reactions (Figure 4). The
addition of supernatant from the HET-s with domain V of 23S rRNA reaction showed the fastest and
highest increase in light scattering suggesting that it contained “seeds” for HET-s aggregation. Thus,
it could be concluded that domain V rRNA blocks the formation of large aggregates of HET-s, but
facilitates the accumulation of small soluble aggregates. These can work as “seeds” to induce large
aggregation in fresh HET-s solution.
Figure 3. TEM images of HET-s without (A) or with (B–D) different RNAs. HET-s protein stored in
urea was diluted to 5 µM and incubated in 50 mM Tris-HCl pH 7.5 at 37 ◦C for a day without or with
1 µM in vitro transcribed domain V of E. coli 23S rRNA (B), DHFR mRNA (C) and HCA mRNA (D).
Then, TEM images were produced using a Hitachi H-7100 transmission electron microscope (Hitachi,
Tokyo, Japan).
Figure 4. Aggregation kinetics of HET-s with “seeds” from matured HET-s aggregation reactions,
conducted with or without domain V of 23S rRNA The aggregation kinetics is followed by Rayleigh
light scattering at 402 nm (excitation 400 nm), without (blue trace) or with domain V of 23S rRNA
(1 µM; pink trace) and with “seeds” from previous HET-s aggregation reactions, conducted without
or with domain V of 23S rRNA. See Materials and methods for details. The traces in the figure are
representative out of three independent replicates.
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2.5. The Interaction Map of HET-s on Domain V rRNA
Domain V of 23S rRNA was found to be an effective suppressor of fibrillary aggregation of HET-s.
Here, we have mapped the interaction sites of HET-s with domain V rRNA using UV cross-linking
followed by primer extension (by reverse transcription) assay. As shown in Figure 5, UV cross-linking
of HET-s immediately after dilution of the denaturant produced reverse transcription “road-blocks”
on almost the same nucleotides on domain V rRNA as other control protein substrates, namely
HCA, DHFR and bovine carbonic anhydrase (BCA).. The main interaction sites were U2474–A2476,
U2492–G2494, G2553–C2556, A2560–A2564 and U2585–G2588. Interestingly, the same sites were
reported earlier for PFAR [28]. Thus, this observation suggests that PFAR might be involved in the
prevention of HET-s aggregation. To test that we used a mutant variant of domain V rRNA and tested
in HET-s aggregation assay.
Figure 5. Primer extension or “road-block” analysis of domain V of 23S rRNA after UV cross-linking of
HET-s and other protein while refolding. HET-s and three other protein controls were subjected to
UV cross-linking with domain V of 23S rRNA E. coli immediately after dilution from the denaturant
as mentioned in the Materials and Methods. Then, primer extension was performed using reverse
transcriptase and the products were run on a sequencing gel—without any protein (Lane 1), with
HCA (Lane 2), DHFR (Lane 3), BCA (Lane 4) and HET-s (Lane 5). The first four lanes in the left show
sequencing ladders as indicated on top. The road-block sites are labeled with nucleotide numbers
corresponding to E. coli 23S rRNA. Part of this gel was originally published in the Journal of Biological
Chemistry [28]. © the American Society for Biochemistry and Molecular Biology.
2.6. Effect of Mutations in Domain V rRNA in HET-s Aggregation
HET-s protein produced a strong block in the residues UAG2586-88 (E. coli numbering) on domain
V rRNA. These residues are highly conserved and mutation in these bases showed defects in PFAR. We
tested the effect of UAG2586-88CCA mutant domain V rRNA on HET-s aggregation by light scattering
and ThT binding assays. In both assays, UAG2586-88CCA domain V rRNA showed less efficiency in
reducing HET-s aggregation compared to the wild-type domain V rRNA (Figure 6B,C), suggesting
that interaction with these bases of domain V rRNA might have an impact on reduction of HET-s
aggregation. However, it should be mentioned that PFAR was completely lost with this mutant domain
V rRNA, while in case of HET-s aggregation it only caused partial reduction. Further, we tested this
mutant domain V rRNA in UV cross-linking followed by primer extension assay. No binding was seen
on the altered bases while other interaction sites remained unchanged (Figure 6A). This result suggests
that HET-s interacts with domain V rRNA in a sequence-dependent manner. However, whether this
interaction is directly causative for the reduction of HET-s aggregation or not remains to be answered.
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Figure 6. The effect of UAG2586–88CCA mutation in domain V rRNA on HET-s aggregation and
interaction map. (A) The primer extension map of sections of domain V of 23S rRNA (E. coli) without
any protein (Lane 1) or with HET-s UV cross-linked to wild-type (Lane 2), or mutant domain V rRNA
with mutations UU2561–62AA (Lane 3) and UAG2586-88CCA (Lane 4). Only the road-block site
U2585-G2588 is shown in the box; (B,C) HET-s aggregation with UAG2586-88CCA mutant variant of
domain V rRNA checked by light scattering (B) and ThT binding (C) using the setting described in
materials and methods. Figures are representative of three independent triplicates.
3. Discussion
How newly synthesized polypeptide chains are folded in the living cells is one of the major
questions in biological science. Several molecular chaperones were shown to be part of the process,
which suggests that the cells have evolved multiple processes to ensure protein folding under various
circumstances. Ribosomes from all three kingdoms of life were shown to have activity in refolding
denatured proteins to their active state [21]. This PFAR commonly called PFAR was assigned to
the large subunit of the ribosome, and more precisely to the domain V of the largest rRNA, which
belongs to the large ribosomal subunit and holds the peptidyl transferase center [42]. A recent study
demonstrated that ribosomes can also disaggregate various folding intermediates [38]. However,
whether PFAR and protein disaggregation are related to two sides of the same coin remains elusive.
The interaction of the prion proteins with RNAs, resulting in modulation of their folding and
aggregation pathways is an established fact [37,43,44]. As mentioned in the introduction, earlier results
with the antiprion compounds 6AP and GA indicated a close involvement between PFAR and prion
processes. These compounds were primarily identified by red/white screening in yeast [PSI+] system
and further confirmed in the mammalian prion system [45,46]. The red/white colony screening method
is based on the principle that in [PSI+] cells, most of the Sup35 protein, a subunit (also called eRF3) of
the eukaryotic release factor, is sequestered into protein aggregates and thus unavailable to function
in translation termination. As a result, [PSI+] causes an increased tendency to read through the stop
codons. The ade1-14 allele contains an opal stop codon in the open reading frame of ADE1. When
Sup35p is in its aggregated, prion conformation ([PSI+] cells), ribosomes read through this opal codon,
which allows cells to grow on adenine-deficient medium (SD-Ade) and produce regular white colonies.
However, when Sup35p is in its normal soluble form ([PSI-] cells), translation of the ade1-14 allele
terminates at the opal codon preventing cells from growing on SD-Ade and leading to red colonies due
to the formation of a metabolic byproduct. The treatment of [PSI+] cells with 6AP and GA results in
the formation of red [PSI-] daughter colonies, suggesting that the prion phenotype was reversed. This
would mean that either, in those 6AP/GA-treated cells, Sup35p could not aggregate to the inactive large
amyloid form or alternatively, that prion propagation to daughter cells by means of small aggregates
or “seeds“ formation was blocked. Since 6AP and GA bind specifically to rRNA and the binding
is sensitive to mutations on domain V rRNA [28,46], PFAR was already implied in prion processes
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in vivo. However, the question remained whether PFAR is involved in “seeds” formation and thus in
prion propagation, or alternatively—in large prion fibril formation.
In coherence with earlier reports [31,32], our results with HET-s prion protein as a model system,
shed light on the involvement of the ribosome in the prion propagation processes. We find that rRNA,
especially domain V of 23S/25S/28S rRNA, can prevent spontaneous aggregation of the HET-s prions
into large, amyloid fibrils. Instead, it can facilitate the accumulation of the small oligomeric aggregates,
which like prion “seeds”, can induce de novo fibrillar aggregation of HET-s. Our primer extension
data presented in Figure 5 demonstrate that HET-s interacts with domain V of 23S rRNA using the
nucleotides, which were identified for PFAR in relation to other nonprionogenic proteins [29,30,47].
Moreover, mutation of those nucleotides abolishes or diminishes the interaction (Figure 6A), also
similar to what was seen earlier for other proteins [28]. This leads to the conclusion that HET-s
interaction with rRNA is associated with PFAR. Thus, combining our observations together with earlier
reports we propose that most likely, PFAR prevents misfolding of HET-s proteins and thereby blocks
the formation of large, fibrillar and amorphous aggregates (Figure 2). However, PFAR does not inhibit
HET-s aggregation completely leading to the formation of the oligomeric HET-s “seeds”. Our analyses
are presented in a simple model in Figure 7. Our in vitro biochemical results can be extrapolated to
explain the in vivo results of 6AP and GA action in [PSI+] yeast cells. In full agreement with the results
and analyses presented by Voisset et al., we propose that PFAR is involved in the propagation of the
[PSI+] prions by oligomeric “seeds” formation [32]. 6AP and GA primarily inhibit PFAR by binding to
the domain V of 25S rRNA [28]. As a consequence, “seeds” formation diminishes and hence, prion
propagation stops. Combining evidence from our current results and earlier works, we conclude that
the rRNA-based PFAR governs yeast prion propagation by mediating a subtle balance between fibrillar
(insoluble) and (soluble) oligomeric aggregates. The universality of this mechanism remains to be
tested in other prion systems. However, given the highly conserved sequence, structure and functions
of the domain V of the major rRNA of the large ribosomal subunit from all kingdoms of life, it will
not be surprising if such a universal mechanism exists. This will, undoubtedly, be of fundamental
scientific and therapeutic interest in the field of prion and neurodegenerative diseases.
Figure 7. Schematic illustration of the HET-s aggregation pathway and the role of domain V of 23S
rRNA. Monomeric HET-s spontaneously undergoes a conformational change to form prefibrillar
oligomers, which eventually aggregate to large insoluble amyloid fibrils. However, when it interacts
with domain V of 23S rRNA (or other active rRNA components) PFAR prevents misfolding of HET-s
and thereby blocks the formation of large, fibrillar (and amorphous) aggregates. Instead, an alternative
pathway comes into action and HET-s folds to form soluble “oligomeric seeds” capable of promoting
de novo prion propagation.
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4. Materials and Methods
4.1. Chemicals and Buffers for Experiments
The analytical grade chemicals were purchased from Sigma-Aldrich (Saint Louis, MO, USA) and
Merck (Kenilworth, NJ, USA). Talon Resin (CLONTECH) was purchased from TaKaRa Bio Europe AB
(Göteborg, Sweden). The reagents for in vitro transcription, primer extension assay and extraction
of RNAs were purchased from Macherey-Nagel (Dueren, Germany) and ThermoFisher Scientific
(Uppsala, Sweden).
4.2. HET-s Protein Expression and Purification
The pET21 clone of full-length HET-s with C-terminal histidine-tag was kindly provided by Sven
J. Saupe (University of Bordeaux, Bordeaux, Aquitaine, France). The plasmid was transformed into E.
coli BL21(DE3) pLysS cells. Bacteria were grown to 0.5 OD in 2× YT medium and then induced by the
addition of 1 mM isopropyl-β-d-thiogalactoside. Four hours after induction, the cells were harvested
by centrifugation and either stored at −80 ◦C or proceeded with purification. Cells were lysed in lysis
buffer (100 mM potassium phosphate buffer, pH 8.0). The lysate was centrifuged for 20 min at 20,000×
g. The pellet was washed in lysis buffer and resuspended in denaturing buffer (8 M guanidinium-HCl
(Gdn-HCl) in lysis buffer). The lysate was incubated with Talon Resin (CLONTECH) for 1 h at 20 ◦C,
and the resin was washed with washing buffer (8 M urea in lysis buffer). The HET-s protein was eluted
from the resin in the denatured state with elution buffer (200 mM imidazole in washing buffer) and
stored at 4 ◦C.
4.3. In Vitro Transcription and Extraction of Various RNAs
Plasmids containing DNA sequences for domain V of large rRNA from different species (Human,
Human mitochondria, bacteria B. subtilis, yeast S. cerevisiae) and PCR products containing sequences
of 23S rDNA from E. coli, mRNAs of HCA (783 nucleotides (nt)), DHFR (498 nt) and were used as
DNA templates for transcription. The in vitro transcriptions were done using T7 RNA polymerase
according to [30] and the RNAs were purified from free nucleotides by using RNA purification kit
(Macherey-Nagel). Bulk tRNAs were isolated from E. coli MRE600 by phenol-chloroform treatment [48].
The quality of the RNAs was checked by running into denaturing urea polyacrylamide gel. The length
of the 23S rRNA domains were as domain V (595 nt), domain IV (360 nt) and domain II (725 nt).
4.4. Light Scattering Assay
Rayleigh light scattering is often used to monitor protein aggregation since the intensity of the
scattered light increases with the increase in the size and density of the particles. For studying HET-s
aggregation, 8 M urea denatured HET-s was diluted 50 times in 50 mM Tris-HCl buffer (pH 7.5) to a
final concentration of 5 µM and incubated without or with different RNA samples overnight at 37 ◦C.
Then, Rayleigh light scattering from the samples was measured at 402 nm (excitation 400 nm, excitation
and emission slit 2.5 nm) with a HITACHI F-7000 steady-state fluorescence spectrophotometer (Tokyo,
Japan) at 25 ◦C. For kinetics of HET-s aggregation light scattering at 402 nm was followed with time
with the same setup as described above, alone or with various RNAs/“seeds“ from previous HET-s
aggregation reactions. All measurements were performed at least in triplicates and the data represent
the average of three to five independent experiments.
4.5. ThT Binding Assay
The HET-s samples with/without RNAs were treated in the same way as in the light scattering
assay. ThT (obtained from Sigma) solutions were prepared in double-distilled water and filtered
through a 0.22 µm syringe filter. To the overnight incubated HET-s samples ThT was added in
the ThT:HET-s ratio 20:1 incubated 3 min at 25 ◦C, and then ThT fluorescence (between 465 and
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565 nm, excitation and emission slit width 5 nm) was recorded using a fluorescence spectrophotometer
(HITACHI, F-7000) with excitation at 450 nm. All measurements were done in triplicates and the data
represent the average of all three experiments after background subtraction.
4.6. Primer Extension Assay for Detecting HET-s Binding Sites on Domain V rRNA
30 µM HET-s protein stored in urea was diluted 100 times in refolding buffer containing domain
V variants of 23S rRNA from E. coli (300 nM), and UV cross-linking was performed immediately
in a Bio-Rad GS Gene Linker TM instrument (Hercules, CA, USA), with 254 nm UV irradiation
(600 mJ) [49]. For comparison, three unrelated proteins—BCA, HCA and DHFR, were denatured
with 6 M Gdn-HCl and subjected to UV cross-linking immediately after dilution of the denaturant.
The samples were kept on ice during irradiation to prevent heat damage to the RNA. The irradiated
samples were precipitated by salt/ethanol and washed with 70% ethanol for primer extension. Primer
5′-ACCCCGGATCCGCGCCCACGGCAGATAGG-3′ was labeled with [γ-32P] dATP at 37 ◦C using
T4 polynucleotide kinase for 1 h by the 5′-end-labeling method [50]. The primer extension was done
using the same procedure as described in [28].
4.7. TEM
HET-s protein stored in urea was diluted to 5 µM and incubated in 50 mM Tris-HCl pH 7.5 at
37 ◦C for a day without or with 1 µM in vitro transcribed different RNAs. For morphological analysis
of aggregates formed in vitro, samples were diluted 1:4 in 50 mM pH 7.5 Tris-HCl. A solution of each
sample (10 µL) was applied to a carbon-coated copper grid and negatively contrasted with 2.5% uranyl
acetate in 50% ethanol. Samples were studied at 75 kV in a Hitachi H-7100 transmission electron
microscope (Tokyo, Japan), and images were obtained with Gatan 832 Orius SC1000 (Gatan Inc.,
Pleasanton, CA, USA).
4.8. Cross-Seeding Assay
First, 8 M urea denatured HET-s was diluted 50 times in 50 mM Tris-HCl buffer (pH 7.5) to a
final concentration of 5 µM and incubated without or with domain V of 23S rRNA (1 µM) overnight
at 37 ◦C to induce aggregation. The overnight samples were centrifuged at 14,000 rpm for 30 min at
room temperature and the supernatant was separated from the aggregated pellet. 10 µL of the cleared
supernatant from each reaction was added as “seeds” to the fresh dilutions of 8 M urea denatured
HET-s (500 µL). The aggregation kinetics was followed by monitoring Rayleigh light scattering at
402 nm (excitation 400 nm, excitation and emission slit 2.5 nm) with a HITACHI F-7000 steady-state
fluorescence spectrophotometer as described under “Light Scattering Assay”, we added as controls, we
also followed the kinetics of HET-s aggregation with and without domain V of 23S rRNA (1 µM). The
fluorescence data are plotted against time to follow the time course of HET-s aggregation with/without
“seeds“. All experiments were done in triplicates.
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